Creso Pharma set to be the first ASX listed entrant in new market
Finfeed
Archived
Mar 15, 2021
Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed an agreement to acquire Halucenex Life Sciences Inc. (Halucenex), an established psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.